Rapamycin Treatment Attenuates Angiotensin II -induced Abdominal Aortic Aneurysm Formation via VSMC Phenotypic Modulation and Down-regulation of ERK1/2 Activity

Abstract

The aim of the present study is to address the effect of rapamycin on abdominal aortic aneurysm (AAA) and the potential mechanisms. A clinically relevant AAA model was induced in apolipoprotein E-deficient (ApoE-/-) mice, in which miniosmotic pump was implanted subcutaneously to deliver angiotensin II (Ang II) for 14 days. Male ApoE-/- mice were randomly divided into 3 groups: saline infusion, Ang II infusion, and Ang II infusion plus intraperitoneal injection of rapamycin. The diameter of the supra-renal abdominal aorta was measured by ultrasonography at the end of the infusion. Then aortic tissue was excised and examined by Western blotting and histoimmunochemistry. Ang n with or without rapamycin treatment was applied to the cultured vascular smooth muscle cells (VSMCs) in vitro. The results revealed that rapamycin treatment significantly attenuated the incidence of Ang II induced-AAA in ApoE-/- mice. Histologic analysis showed that rapamycin treatment decreased disarray of elastin fibers and VSMCs hyperplasia in the medial layer. Immunochemistry staining and Western blotting documented the increased phospho-ERK1/2 and ERK1/2 expression in aortic walls in Ang II induced-AAA, as well as in human lesions. Whereas in the rapamycintreated group, decreased phospho-ERKl/2 expression level was detected. Moreover, rapamycin reversed Ang II -induced VSMCs phenotypic change both in vivo and in vitro. Based on those results, we confirmed that rapamycin therapy suppressed Ang II -induced AAA formation in mice, partially via VSMCs phenotypic modulation and down-regulation of ERK1/2 activity.

Keywords

rapamycin / abdominal aortic aneurysm / angiotensin n / extracellular signalregulated kinase / vascular smooth muscle cells / phenotypic modulation

References

[1] GolledgeJ, NormanPE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis, 2011, 217(1): 57-63

[2] NordonIM, HinchlifFeRJ, LoftusIM, et al.. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol, 2011, 8(2): 92-102

[3] WangY, Ait-OufellaH, HerbinO, et al.. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin Il-infused mice. J Clin Invest, 2010, 120(2): 422-432

[4] GhoshalS, LoftinCD. Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice. PLoS One, 2012, 7(1l): e44 369

[5] PLoS One, 2012, 7(4):

[6] SatohK, NigraP, MatobaT, et al.. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med, 2009, 15(6): 649-656

[7] JohanningJM, FranklinDP, HanDC, et al.. Inhibition of inducible nitric oxide synthase limits nitric oxide production and experimental aneurysm expansion. J Vase Surg, 2001, 33(3): 579-586

[8] AilawadiG, EliasonJL, UpchurchGRJr. Current concepts in the pathogenesis of abdominal aortic aneurysm. J Vase Surg, 2003, 38(3): 584-588

[9] PatelMI, GhoshP, MelroseJ, et al.. Smooth muscle cell migration and proliferation is enhanced in abdominal aortic aneurysms. Aust N Z J Surg, 1996, 66(5): 305-308

[10] MaoN, GuT, ShiE, et al.. Phenotypic switching of vascular smooth muscle cells in animal model of rat thoracic aortic aneurysm. Interact Cardiovasc Thorac Surg, 2015, 21(1): 62-70

[11] AilawadiG, MoehleCW, PeiH, et al.. Smooth muscle phenotypic modulation is an early event in aortic aneurysms. J Thorac Cardiovasc Surg, 2009, 138(6): 1392-1399

[12] SavoiaC, BurgerD, NishigakiN, et al.. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med, 2011, 13: ell

[13] EguchiS, DempseyPJ, FrankGD, et al.. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem, 2001, 276(11): 7957-7962

[14] DaughertyA, CassisL. Angiotensin II and abdominal aortic aneurysms. Curr Hypertens Rep, 2004, 6(6): 442-446

[15] DaughertyA, ManningMW, CassisLA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest, 2000, 105(11): 1605-1612

[16] ThompsonRW. Reflections on the pathogenesis of abdominal aortic aneurysms. Cardiovasc Surg, 2002, 10(4): 389-394

[17] McCormickML, GavrilaD, WeintraubNL. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vase Biol, 2007, 27(3): 461-469

[18] HayN, SonenbergN. Upstream and downstream of mTOR. Genes Dev, 2004, 18(16): 1926-1945

[19] LiptonJO, SahinM. The neurology of mTOR. Neuron, 2014, 84(2): 275-291

[20] HolmesD J, LeonMB, MosesJW, et al.. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation, 2004, 109(5): 634-640

[21] KhanW, FarahS, DombAJ. Drug eluting stents: developments and current status. J Control Release, 2012, 161(2): 703-712

[22] LiW, LiQ, QinL, et al.. Rapamycin inhibits smooth muscle cell proliferation and obstructive arteriopathy attributable to elastin deficiency. Arterioscler Thromb Vase Biol, 2013, 33(5): 1028-1035

[23] Am J Physiol Endocrinol Metab, 2012, 302(2):

[24] Am J Physiol Heart Circ Physiol, 2004, 287(3):

[25] Am J Physiol Cell Physiol, 2004, 286(3):

[26] ZuckermannA, KeoghA, Crespo-LeiroMG, et al.. Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency. Am J Transplant, 2012, 12(9): 2487-2497

[27] RayJL, LeachR, HerbertJM, et al.. Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sei, 2001, 23(4): 185-188

[28] Rodriguez-VitaJ, Sanchez-LopezE, EstebanV, et al.. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation, 2005, 1ll(19): 2509-2517

[29] GhoshA, DiMustoPD, EhrlichmanLK, et al.. The role of extracellular signal-related kinase during abdominal aortic aneurysm formation. J Am Coll Surg, 2012, 215(5): 668-680

[30] MoranCS, JoseRJ, MoxonJV, et al.. Everolimus limits aortic aneurysm in the apolipoprotein E-deficient mouse by downregulating C-C chemokine receptor 2 positive monocytes. Arterioscler Thromb Vase Biol, 2013, 33(4): 814-821

[31] LawrenceDM, SinghRS, FranklinDP, et al.. Rapamycin suppresses experimental aortic aneurysm growth. J Vase Surg, 2004, 40(2): 334-338

[32] LesauskaiteV, TanganelliP, SassiC, et al.. Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. Hum Pathol, 2001, 32(9): 1003-1011

[33] MartinKA, MerenickBL, DingM, et al.. Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling. J Biol Chem, 2007, 282(49): 36 112-36 120

[34] HayashiK, TakahashiM, KimuraK, et al.. Changes in the balance of phosphoinositide 3-kinase/protein kinase B (Akt) and the mitogen-activated protein kinases (ERK/p38MAPK) determine a phenotype of visceral and vascular smooth muscle cells. J Cell Biol, 1999, 145(4): 727-740

[35] KyawM, YoshizumiM, TsuchiyaK, et al.. Antioxidants inhibit JNK and p38MAPK activation but not ERK1/2 activation by angiotensin IT in rat aortic smooth muscle cells. Hypertens Res, 2001, 24(3): 251-261

[36] GriendlingKK, MinieriCA, OllerenshawJD, et al.. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res, 1994, 74(6): 1141-1148

[37] SanoM, FukudaK, SatoT, et al.. ERK and p38 МАРК, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ Res, 2001, 89(8): 661-669

[38] WilkieN, MortonC, NgLL, et al.. Stimulated mitogen-activated protein kinase is necessary but not sufficient for the mitogenic response to angiotensin II. A role for phospholipase D. J Biol Chem, 1996, 271(50): 32 447-32 453

[39] HolmTM, HabashiJP, DoyleJJ, et al.. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science, 2011, 332(6027): 358-361

[40] MendozaMC, ErEE, BlenisJ. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci, 2011, 36(6): 320-328